Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53

BACKGROUND: Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines available, but they are not from Chinese populations. METHODS: Three immortali...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Cell Int
Autori principali: Zhou, Fei, Zhang, Yanhua, Xu, Xiufang, Luo, Jingfeng, Yang, Fang, Wang, Linbo, Xie, Shuduo, Sun, Jihong, Yang, Xiaoming
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Primary Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6098622/
https://ncbi.nlm.nih.gov/pubmed/30140169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-018-0617-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi